marketcap
Facebook
Twitter
Telegram
Report an ErrorAnnual report 2024
added 10-25-2025
Kamada Ltd. Retained Earnings 2011-2025 | KMDA
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Kamada Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -43.9 M | -52.2 M | -73.7 M | -95 M | -102 M | -95.6 M | -83.5 M | -72.8 M | -80.7 M | -88.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -43.9 M | -102 M | -78.8 M |
Quarterly Retained Earnings Kamada Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -46.2 M | -41.2 M | - | - | -43.9 M | -45.6 M | - | - | -61.1 M | - | - | - | -83 M | - | - | - | -105 M | - | - | - | -111 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -41.2 M | -111 M | -67.1 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Graybug Vision
GRAY
|
-146 M | $ 0.44 | -11.23 % | $ 9.65 M |  USA |
 |
AgeX Therapeutics
AGE
|
-131 M | $ 11.3 | -10.17 % | $ 12.2 K | - |
 |
Galera Therapeutics
GRTX
|
-456 M | $ 0.14 | -32.59 % | $ 7.61 M | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
-578 M | $ 4.37 | -1.58 % | $ 28.1 M |  China |
 |
Axon Enterprise
AXON
|
812 M | $ 723.51 | -1.19 % | $ 54.8 B | USA |
 |
Caladrius Biosciences
CLBS
|
-548 M | $ 0.43 | -16.75 % | $ 25.8 M | USA |
 |
Sorrento Therapeutics
SRNE
|
-1.39 B | $ 0.27 | -29.58 % | $ 126 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-8.61 B | $ 184.71 | 0.49 % | $ 251 B |  Cayman-islands |
 |
Heron Therapeutics
HRTX
|
-1.92 B | $ 1.2 | 3.02 % | $ 183 M | USA |
 |
ContraFect Corporation
CFRX
|
-326 M | $ 1.47 | -5.16 % | $ 5.39 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
-901 M | $ 4.93 | 1.02 % | $ 90.8 M |  Britain |
 |
Midatech Pharma plc
MTP
|
-122 M | $ 0.29 | -18.52 % | $ 27.3 M | Britain |
 |
Advaxis
ADXS
|
-197 M | $ 0.31 | -9.65 % | $ 45.9 M | USA |
 |
Heat Biologics, Inc.
HTBX
|
-131 M | $ 3.93 | -5.76 % | $ 99.8 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
-1.06 B | $ 6.2 | - | $ 154 M | USA |
 |
Zymeworks
ZYME
|
-683 M | $ 6.42 | - | $ 404 M |  Canada |
 |
Aeterna Zentaris
AEZS
|
-335 M | $ 5.72 | 5.93 % | $ 314 M | Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
-201 M | $ 10.5 | - | $ 231 M | USA |
 |
Kadmon Holdings, Inc.
KDMN
|
-444 M | $ 9.5 | - | $ 1.7 B | USA |
 |
BioDelivery Sciences International
BDSI
|
-256 M | $ 2.58 | -4.8 % | $ 255 M | USA |
 |
Zosano Pharma Corporation
ZSAN
|
-362 M | $ 0.56 | 7.23 % | $ 2.72 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | $ 0.5 | - | $ 7.46 M |  Israel |
 |
Kiromic BioPharma
KRBP
|
-150 M | $ 3.15 | 6.61 % | $ 3.08 M | USA |
 |
Acceleron Pharma Inc.
XLRN
|
-711 M | $ 179.68 | - | $ 10.9 B | USA |
 |
Albireo Pharma
ALBO
|
-301 M | $ 44.15 | -0.23 % | $ 916 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
-608 M | $ 0.32 | - | $ 23.9 M | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
-249 M | $ 18.44 | - | $ 1.94 B | Canada |
 |
Kaleido Biosciences
KLDO
|
-364 M | $ 0.29 | -3.69 % | $ 12.4 M | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
-232 M | $ 2.19 | - | $ 105 M | USA |
 |
Humanigen
HGEN
|
-682 M | $ 0.04 | -81.12 % | $ 4.28 M | USA |
 |
Aptinyx
APTX
|
-353 M | $ 0.06 | -39.0 % | $ 4.57 M | USA |
 |
Tyme Technologies
TYME
|
-137 M | $ 0.31 | 8.07 % | $ 54 M | USA |
 |
Forward Pharma A/S
FWP
|
-14.8 M | $ 2.64 | -0.75 % | $ 18.7 M |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | $ 0.39 | - | $ 26.5 M | USA |
 |
Celyad Oncology SA
CYAD
|
-91.8 M | $ 0.47 | - | $ 12.5 M |  Belgium |
 |
Brickell Biotech
BBI
|
-172 M | $ 2.11 | -5.38 % | $ 6.06 M | USA |
 |
Genocea Biosciences
GNCA
|
-408 M | $ 0.05 | -15.0 % | $ 3.04 M | USA |
 |
Codiak BioSciences
CDAK
|
-325 M | $ 0.06 | -55.98 % | $ 2.15 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-349 M | $ 8.37 | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
-223 M | $ 3.17 | 1.93 % | $ 17.4 M | USA |
 |
Novo Nordisk A/S
NVO
|
63.8 B | $ 49.14 | -0.62 % | $ 421 B | Danmark |
 |
Calithera Biosciences
CALA
|
-491 M | $ 0.37 | -10.95 % | $ 876 K | USA |
 |
Forma Therapeutics Holdings
FMTX
|
-230 M | $ 20.01 | - | $ 958 M | USA |
 |
Oncolytics Biotech
ONCY
|
-367 M | $ 1.09 | -8.58 % | $ 115 M | Canada |
 |
Arena Pharmaceuticals
ARNA
|
-2.12 B | $ 49.55 | -6.81 % | $ 3.04 B | USA |
 |
ORIC Pharmaceuticals
ORIC
|
-563 M | $ 12.52 | -4.86 % | $ 873 M | USA |
 |
Sierra Oncology
SRRA
|
-941 M | $ 54.89 | -0.05 % | $ 1.34 B | Canada |
 |
Regulus Therapeutics
RGLS
|
-513 M | $ 8.16 | - | $ 155 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Precigen
PGEN
|
-1.96 B | $ 4.17 | 0.72 % | $ 1.02 B | USA |